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Free radicalsCoenzyme Q10 (Q10) is present in the circulation mainly in its reduced form (ubiquinol-10; UL10), but
oxidizes quickly ex vivo to ubiquinone-10 (UN10). Therefore, native UL10:UN10 ratios, used as markers
of redox status and disease risk, are difficult to measure. We established an RP-(U)HPLC method with
coulometric detection to measure natively circulating UL10 and UN10 concentrations by adding a ubiquinol/
ubiquinone mixture as an internal standard immediately after plasma preparation. This allowed adjustment
for unavoidable artificial UL10 oxidation as well as for total losses (or gains) of analytes during sample
storage, processing, and analysis because the internal standards exactly paralleled the chemical behavior of
Q10. This technique applied to blood (n= 13) revealed Q10 levels of 680–3300 nM with a mean UL10:UN10
ratio of 95:5, which was inversely associated with total Q10 (r=−0.69; p=0.004). The oxidation of UL10 to
UN10 was equimolar, increased by O2, and decreased by lower temperatures or various degassing methods.
Although UL10 was stable in blood or when pure in organic solvents at 22 °C, its oxidation was catalyzed
dose dependently by α-tocopherol and butylated hydroxytoluene, particularly when present in combination.
Key structural features for the catalytic pro-oxidant properties of phenolic antioxidants included two
substituents vicinal to the phenolic hydroxyl group.ography; UV, ultraviolet; ECD,
aphy/mass spectrometry; UL,
ytoluene; αT, α-tocopherol;
).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Coenzyme Q10 (Q10; Fig. 1), a lipophilic cell membrane com-
ponent and the predominant member among the coenzyme Q species
in humans, functions as an electron carrier in the mitochondrial
respiratory chain as well as an intracellular antioxidant [1–3]. It is
synthesized by human cells, but exposure occurs also through the diet
with daily Q10 and Q9 doses estimated (in Scandinavians) to be 4–5
and 0.4–0.6 mg, respectively [4].
Ubiquinol-10 (UL10), the chemically reduced form of Q10, is a free
radical scavenger, prevents peroxidation damage to cell membranes,
regenerates α-tocopherol, and minimizes the effects of oxidative
stress by dehydrogenating to ubiquinone-10 (UN10) [5–7]. The UL10:
UN10 ratio is therefore postulated to be a good marker of oxidative
stress [8], whereas total Q10 (TQ10) may indicate general physiologic
events, such as cell death, because dying cells would leak Q10 into
the circulation [5,9–11]. Lower UL10:UN10 ratios have been reported
in older individuals and patients with liver disease, coronary artery
disease, neurodegenerative disease, dyslipidemia, trisomy 21, and
chronic obstructive pulmonary disease [2,9,11–13]. Significant defi-
ciency in skeletal muscle Q10 has been reported in patients withmultisystem mitochondrial encephalomyopathies [14], whereas low
circulating TQ10 levels were associated with cardiovascular diseases
[15,16], ataxia [17], and patients receiving statins [18]. Interestingly,
lower cell TQ10 levels are associated with older age [19] but higher
blood TQ10 levels were observed in adults versus older children [2].
Ubiquinols oxidize quickly in the presence of oxygen and in-
creasingly at temperatures above−70 °C, which renders native levels
difficult to quantitate [20–22]. This has led many investigators to
exclusively report TQ10 [23], by either chemically reducing samples
with NaBH4 [24] or oxidizing them with FeCl3 or CuCl2 [20] before
analysis or by precolumn electrochemical reduction or oxidation [5].
The most popular routine analysis employs reversed-phase HPLC
with absorbance readings at 275 nm [25] or electrochemical detection
to achieve higher sensitivity. Mass spectrometric detection has also
been applied more recently and is a method that is highly selective,
but requires the availability of expensive instrumentation [3,26],
whereas fluorescence monitoring is not recommended because of
its low sensitivity [27]. Simultaneous analysis of UL10 and UN10
can be achieved by chromatographic separation followed by electro-
chemical (preferably coulometric) detection via oxidation of UL10
at positive voltage and reduction of UN10 with negative voltage
[5,26]. This is easier to perform than employing a reduction column
after chromatographic separation and monitoring by electrochemical
detection with positive voltages [25].
Internal standards of various Q10 analogs (Q6, Q7, Q9) have been
employed [5,20,28], including alkoxy analogs of Q10 [26,29]. However,
Fig. 1. Molecular structure of ubiquinols and ubiquinones. Interconversion occurs
readily by redox reaction and is easily achieved electrochemically by dehydrogenation
(positive voltage) and by hydrogenation (negative voltage).
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for the absolute loss of analytes during sample preparation and
measurement and not for the conversion of native UL during these
processes or during storage.
We intended to establish a simple, fast, sensitive, and accurate
HPLC method to measure TQ10 as well as natively circulating UL10
and UN10 concentrations. Realizing that the latter levels change
continuously after blood is drawn, our aim was to find an internal
standard that allows adjustment for artificial UL10 oxidation as
well as for total losses (or gains) of analytes during sample storage,
processing, and analysis. We also aimed to evaluate determinants
for the oxidation of UL10.
Materials and methods
Chemicals and reagents
Ubiquinone-4, ubiquinone-6, UN10, and α-tocopherol (αT) were
purchased from Sigma–Aldrich (St. Louis, MO, USA). Ubiquinone-9
(UN9) was obtained from Fluka (Sigma–Aldrich). Tocol was pur-
chased from Matreya (Pleasant Gap, PA, USA). Sodium borohydride,
dimethylamino pyridine, sodium carbonate, and dodecanoic anhy-
dride were obtained from Sigma–Aldrich. Methanol, hexane, and
acetonitrile were HPLC grade from Fisher (Pittsburgh, PA, USA). Hexane
and methanol were kept refrigerated before and during extractions.
Peroxide test strips (WaterWorks Peroxide Check, Industrial Test
Systems, Rock Hill, SC, USA) with a sensitivity b0.5 ppm were used for
the determination of peroxide levels.
Plasma preparation and extraction
Venous blood was collected into green-top Li-heparin Vacutainers,
twice from 3 and once from 13 healthy volunteers (ages 23–55; mean
41 years). This was approved by the Committee on Human Subjects of
the University of Hawaii and all volunteers signed the consent form.
The blood was kept at room temperature to examine UL10 oxidation
rates during various times followed by processing or the blood was
processed immediately by centrifugation at 1050×g for 20 min at
4 °C. The supernatant plasmawas aliquotted into individual cryogenic
vials and either frozen at −80 °C as such or after adding 200 µl UL9:
UN9 mixture (95:5 in refrigerated methanol; total ca. 0.6 µM) to
200 µl plasma in 1-ml polypropylene tubes. Plasma preparation
followed by storage in −80 °C freezers could be performed as fast
as within 40 min.
HPLC
System 1 (extraction and analysis of UN10 with other lipid-phase
micronutrients)
Carotenoids, retinoids, tocopherols, and UN10 were analyzed by a
well-established HPLC assay with photodiode array detection [30],which is validated by participation in quality assurance programs
organized by the U.S. National Institute of Standards and Technology
(Gaithersburg, MD, USA) [31] and has been successfully applied in
numerous epidemiological and other studies [32–47].
In brief, all procedures before storage of extracted analytes in
amber vials were carried out under yellow light to avoid degradation
of analytes. Plasma (0.20 ml) was mixed with 0.20 ml ethanol
containing butylated hydroxytoluene (BHT) as antioxidant and
four internal standards (tocol, retinyl laurate, δ-tocopheryl laurate,
and n-butyl-β-apo-8′-carotenoate [30]) followed by partitioning into
1.0 ml hexane. The hexane layer was evaporated in amber vials at
room temperature under a stream of nitrogen. The dry extracts
were redissolved in 0.2 ml HPLC mobile phase (see below) followed
by injection of 20 µl into an RP-HPLC system (Model Surveyor;
ThermoFisher, San Jose, CA, USA) consisting of a Spherex C18
analytical column (150×3.2 mm, 3 µm) coupled to a Spherex C18
precolumn (4.0×3.0 mm, 10 µm; both columns from Phenomenex,
Torrance, CA, USA) using isocratic elution with a mobile phase of
650 ml methanol/250 ml dichloromethane/100 ml acetonitrile/2 ml
aq Bis–Tris propane (0.5 M, pH 6.8) and containing 0.25 g/L BHT
(1.14 mM) at 0.3 ml/min. Interassay variability of these analytes
varied between 3 and 9% [30]. UN10 concentrations were determined
from external calibration curves after adjustment for recovery of tocol.
System 2 (extraction and analysis of TQ10 after precolumn electrochemical
oxidation and postcolumn UV detection as UN10)
Analysis of total plasma coenzyme Q10 was carried out by HPLC
(Model Spectra; ThermoFisher) using the hexane extract available from
the procedure described above after redissolving in themobile phase of
HPLC system 1. After coulometric precolumn oxidation using a guard
cell Model 5020 at +0.8 V (ESA, Chelmsford, MA, USA) 20 µL were
separated on a Gemini C18 precolumn (4.0×2.0 mm, approximately
10 µm) directly connected to a Gemini C18 analytical column
(150×2.0 mm, 5 µm; both columns from Phenomenex) using an
isocratic mobile-phase mixture of sodium acetate trihydrate (6.8 g)/
glacial acetic acid (15 ml)/2-propanol (15 ml)/hexane (275 ml)/
methanol (695 ml) [5]. Detection was performed at 275 nm, peak
areas were used for quantitation applying external calibration (range
50–2000 nM determined by absorbance readings), and final values
were adjusted for internal standard (δ-tocopheryl laurate) recovery.
Interassay variability of TQ10 was found to vary between 5 and 7% at
levels of 400 nM.
UL10 levels were calculated by subtracting UN10 from TQ10 levels.
System3 (extraction and analysis of UL andUNbyUVand electrochemical
detection)
After centrifugation of blood, 200 µl plasma was immediately
mixed with 200 µl of a mixture of known concentrations of UL9 and
UN9 in refrigerated methanol (ca. 0.6 and 0.03 µM, respectively) as
internal standards. This mixture was immediately extracted and
analyzed by HPLC or stored at −80 °C. The thawed plasma, spiked
with the UL9/UN9 mixture, was extracted with 200 µl of chilled
hexane by vortexing 1.5 min followed by centrifugation for 5 min at
4 °C and 5082×g. A 100-µl sample of the hexane layer was transferred
to a 200-µl conical insert in an amber HPLC autosampler vial and
injected into a Hypersil Gold C18 column (50 mm×2.1 mm×, 1.9 µm;
ThermoFisher) using a model Surveyor HPLC system (ThermoFisher)
with a 20-µl loop injector using amobile phase of (v/v) 83%methanol,
14% acetonitrile, 3.5% water, 0.04% glacial acetic acid, and (w/v) 0.06%
aq lithium acetate at a flow of 0.25 ml/min modified from a previous
report [5]. UL and UN detection was performed by UV absorbance
at 295 nm and coulometrically using a CoulArray Model 5600A
detector (ESA) with consecutive cell voltages of +0.75, −0.70, and
+0.65 V for maximum response of UL10 and UN10 at the last cell. To
achieve faster turnaround times, ultra-HPLC was performed on a
Model Accela UHPLC system (ThermoFisher) with a Coulochem III
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using the above-listed mobile phase at 0.5–0.7 ml/min.
UL10 and UN10 concentrations were determined from external
calibration curves after adjustment for recovery of the internal
standards UL9 and UN9, respectively. This adjusted for the absolute
loss due to pipetting, injection, spillage, or other factors; for possible
extract concentration due to solvent evaporation; and also for the
conversion from the reduced to the oxidized forms of Q10 during
sample storage, workup, and analysis.
Calibration of UN10 and UL10was required on each day of analysis
to ensure good between-day precision. Because of the fast oxidation,
UL9 and UN9 concentrations in the internal standard mixture were
analyzed on each day of blood processing to determine the references
for recovery calculation purposes.
Calibration
Stock solutions for calibration were prepared by dissolving 10 mg
UN10 in 10 ml hexane followed by absorbance readings using
=14,200 at 275 nm in isopropanol [48]. UL10 stock solutions
were prepared accordingly after reduction from UN10 with NaBH4
(see below) using =3510 at 290 nm in isopropanol, which was
determined after synthesis as shown below. All stock solutions were
confirmed to be of N99% purity by HPLC analysis with coulometric
detection.
Calibrators were prepared by dissolving stock solutions to five to
seven concentrations in the range of approximately 30–1800 nM in the
mobile phase for HPLC system 1 or in chilled hexane for coulometric
detection in system 3 or the mobile phases of the respective HPLC
systems. UL10 and UN10 response factors were used for UL9 and UN9,
respectively, because of identical UV-chromophores and the same
coulometrically responsive structural features plus extremely similar
retention times. Calibration curves were obtained by plotting detector
responses versus calibrator concentrations using best-fit regressions
with Excel 2004 software (Microsoft). Calibration curves were accepted
if r2 values were greater than 0.998.
Syntheses
UL10
UL10 was prepared by mixing 5 µl UN10 (1 mg/ml in hexane)
with 200 µl water containing 10 mg sodium borohydride and 4 ml
ethanol [49]. After incubation for 10 min in the dark, 1 ml water was
added, followed by partitioning into 5 ml hexane. The hexane was
then kept at −20 °C until needed for calibration. UL9 was prepared
similarly by mixing 5 µl UN9 (1 mg/ml in hexane) with 200 µl water
containing 10 mg sodium borohydride and 4 ml ethanol. UL:UN ratios
were usually N200:1, as determined by HPLC analysis.
When needed for spiking, an aliquot (usually 1–1.5 ml) was
removed, dried under nitrogen, redissolved in chilled methanol, and
analyzed by HPLC to determine exact Q9 levels that were subse-
quently used for spiking. Ideally, the UL9:UN9 ratio was kept at 20:1
for spiking purposes.
For the determination of UL10's extinction coefficient (molar
absorptivity), thehexanephasedescribedabovewasdried, thenweighed,
and redissolved in hexane followed by dilutions with isopropanol for
absorbance readings. After absorbance was read the samples were
confirmed to contain UL at N99% purity. Three independent experiments
with multiply repeated absorbance readings yielded a molar extinction
coefficient of 3510 at 290 in isopropanol (cv 3%).
δ-Tocopheryl laurate
δ-Tocopheryl laurate was prepared bymixing δ-tocopherol (25 mg)
and lauric acid anhydride (70 mg) with dimethylaminopyridine
(10 mg) and triethylamine (0.5 ml) in dichloromethane (2 ml). The
mixture was refluxed at 60 °C for 3 h and washed with 1 ml water, andthe dichloromethane layer was separated and condensed under
reduced pressure. The resulting oil was subjected to SPE C18 column
purification and was washed with water andmethanol and eluted with
dichloromethane to give the final product.
Results
Because of the lack of availability of UL10 from commercial sources
we synthesized it by reductionofUN10withNaBH4 [49] anddetermined
UL10's hitherto unknown molar absorptivity (3510 at 289 nm in 1-
propanol; cv 3%) in three independent syntheses with repeated
absorbance readings. This allowed calibrations of all HPLC systems and
the reporting of all coenzyme Q10 levels in molar units.
When we applied our traditional HPLC system for lipid-phase
micronutrients (HPLC system 1) we discovered that plasma hexane
extracts stored at room temperature for several days in the methanol-
based HPLC mobile phase led to a decrease in UL10 concentrations
with a concomitant increase in UN10 levels (Fig. 2A). Our attempts to
quantitate this conversion in this HPLC system were unsuccessful
because the UL10 peak could not be separated from lycopene (and α-
carotene) isomers. As shown by the UV/Vis scan of the UL10 peak a
carotenoid-specific absorbance pattern at 400–470 nmwas present in
addition to the UL10 absorbance at 290 nm (see insets of Fig. 2A). To
provide an affordable alternative for Q10 quantitation, we developed
HPLC system 2, which reliably measures TQ10 after quantitative
precolumn coulometric oxidation of UL10 to UN10 followed by
fast HPLC analysis and UV detection of UN10 (native+precolumn
oxidized forms) at 275 nm. This system was applied successfully
(interassay cv 4–11%) for measurement of plasma hexane extracts
that had been stored at−80 °C for several months andwere known to
be stable regarding TQ10 levels [20]. This system allowed quantitation
of Q9 levels by using tocol or preferably δ-tocopheryl laurate as in-
ternal standard (Fig. 2B).
HPLC system 3 was established to quantitate simultaneously UL10
and UN10 without interference from other plasma lipid phase
micronutrients by employing a HypersilGold C18 column that sepa-
rated ULs and UNs in an empty and late part of the chromatogram,
after elution of retinoids, carotenoids, and tocopherols. Detection was
performed by absorbance at 295 nm and by the approximately 40-fold
more sensitive coulometric detection at +0.7 and −0.7 V for UL
and UN, respectively, as optimized by hydrodynamic voltammograms.
Faster run times could be achieved by increasing the solvent flow,
which required ultra-HPLC hardware (data not shown). UL10 was
relatively stable in blood and also alone in organic solvents at 22 °C
and in the presence of Bis–Tris propane (0.5–1 mM), tocol (b10 µM),
or γ-tocopherol (γT; 2–28 µM); however, it oxidized efficiently and
dose dependently to UN10 when BHT or αT was present in in vitro
experiments (Fig. 3, Table 1). The oxidationwas particularly fast when
BHT was combined with αT or γT and was complete at tocopherol
levels of N13 µM before 24–26.5 h postinitiation (our last measuring
point). In the latter cases hourly conversion rates could not be calcu-
lated because the exact time at which 100% conversion occurred
was unknown (any time in the 8- to 24-h period). Whenever oxi-
dation occurred the conversion rates were usually much faster in
the first 1–3 h than at later hours. The reaction speed was 2- to 4-fold
faster when BHT was combined with αT versus combined with γT.
Interestingly, whenever oxidation of UL10 occurred in the presence of
αT or γT the tocopherol levels stayed at the initial concentrations at
any time monitored as measured by HPLC system 1. This suggested
that αT and γT acted catalytically. Also, the conversion of UL10 to
UN10 occurred in an equimolar fashion as evidenced by the molar
changes of UL10 and UN10 measured by HPLC/UV/ECD after
adjustment for absolute losses by using tocol as an internal standard
(Table 1). This in addition to LC/MS measurements identifying the
ECD signals as predicted (data not shown) excluded the formation of
any other products than UN10 during this reaction of UL10.
Fig. 2. (A) HPLC trace of a plasma hexane extract obtained from aQ10 supplemented subject after storage at 22 °C for several days using system1 resolving tocopherols and retinoids (not
shown) and also carotenoids andQ10.UL10 andUN10 in theplasma trace can be identifiedby typical absorption at 290 and275 nm, respectively (standard andplasmaanalytes are shown
in the upper and lower UV/Vis scan panels, respectively). UL10 coelutes with carotenoids, indicated by absorption in the 450 nm range. Over several days oxidation of UL10 to UN10 is
observed bya decreasingUL10peak,whereas theUN10 signal increases. LYC, lycopene;αCAR,α-carotene;βCAR,β-carotene. (B)HPLC trace of a plasmahexane extract (black) usingHPLC
system 2 after precolumn oxidation and postcolumn monitoring at 275 nm. UN10 and the internal standard δ-tocopheryl laurate (dTL) are resolved from UN9, retinyl laurate (RL), and
tocol (T) (overlaid gray/green traces are standards). All other lipophilic antioxidants are eluted in thefirst 2 min and donot interfere. (C) HPLC trace of a plasma hexane extract usingHPLC
system 3 resolving ULs and UNs after all other lipophilic antioxidants (carotenoids, tocopherols, retinoids) are eluted in the first 5 min. Other lipophilic plasma components (fats,
cholesterol) cause a noisy baseline after elution of UN10. A two- to threefold increase in flow rates decreases run times two- to threefold but requires ultra-HPLC equipment.
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solvents used in the UL10 oxidation reaction diminished the speed of
UL10 conversion (Table 1). Oxidation rates were approximately 20-
fold lower in plasma stored at−80 °C vs room temperature. Similarly,
they were 1.1- to 2.2-fold lower after membrane filtering or by argon
or nitrogen purging of solvents, whereas they were 1.9- to 4.0-fold
less after combined membrane filtering and argon purging. In
contrast, conversion rates were increased by a factor of 1.2–1.3 by
blowing oxygen into the solvents before using them for dissolvingUL10 followed by monitoring its oxidation. This suggested that
oxygen plays a key role during this UL10 conversion. The oxidation
pattern described above for UL10 was, as expected, almost identical
for UL9 (Fig. 3, Table 1). Therefore, adjustment of UL10 or UN10 for
UL9 and UN9, respectively, led to almost unchanged Q10 levels over
time (Fig. 3).
In specimen from Q10 unsupplemented subjects the UL oxidation
rates at 22 °C were minimal in unprocessed blood (b0.1%/h after
1 day), moderate once processed to plasma (0.4–0.6%/h after 8 h),
Fig. 3. Decrease in UL9 (spiked as internal standard) and UL10 (native) concentrations
and concomitant increase in UN9 and UN10 levels in a plasma hexane extract over time
at 22 °C. Very similar oxidation rates of UL9 to UN9 and UL10 to UN10 were observed.
Therefore, UL10 levels adjusted for UL9 and UN10 levels adjusted for UN9 remained
little changed. This pattern was also observed with authentic Q9 and Q10 standards
when dissolved in solvents containing α-tocopherol or BHT. However, almost no
change over time at room temperature occurred when ubiquinols were dissolved in
organic solvents alone (see Table 1).
Table 1
Rate of in vitro UL10 oxidation to UN10 (%/h)
Hours BTP or BHT
No
additiona
0.5 mM
BTP
1.0 mM
BTP
No
additiona
1.1 mM
BHT
2.3 mM
BHT
1 b0.1% b0.1% b0.1% b0.1% b0.1% b0.1%
3 b0.1% b0.1% b0.1% b0.1% b0.1% 1.8%
5 b0.1% b0.1% b0.1% b0.1% 0.9% 1.0%
8 b0.1% b0.1% b0.1% b0.1% 0.6% 0.8%
24–26.5 b0.1% b0.1% b0.1% b0.1% 0.8% 1.1%
αT
No
additiona
2.6 µM
αT
13.2 µM
αT
25.5 µM
αT
31.3 µM
αT
50.4 µM
αT
1 b0.1% 1.3% 3.8% 1.0% 4.3% 6.1%
3 b0.1% 0.4% 1.5% 1.6% 2.5% 3.3%
5 b0.1% 0.3% 1.0% 2.2% 2.8% 2.9%
8 b0.1% 0.2% 0.6% 2.0% 3.2% 4.2%
24–26.5 b0.1% 0.2% 0.7% 1.9% 2.7% 3.1%
αT + 1.1 mM BHT+0.5 M BTP
BHT+BTP
alone
2.6 µM
αT
13.2 µM
αT
25.5 µM
αT
50.4 µM
αT
1 1.4% 2.9% 10.6% 18.1% 34.8%
3 0.8% 2.4% 5.9% 10.0% 17.9%
5 0.8% 2.6% 6.7% 9.8% 15.2%
8 0.7% 2.5% 7.4% 10.0% N12.5%
24–26.5 1.0% 2.2% N4.2% N4.2% N4.2%
γT
No additiona 1.7 µM
γT
2.9 µM
γT
5.3 µM
γT
13.7 µM
γT
27.6 µM
γT
1 b0.1% b0.1% b0.1% b0.1% b0.1% b0.1%
3 b0.1% b0.1% b0.1% b0.1% b0.1% b0.1%
5 b0.1% b0.1% b0.1% b0.1% b0.1% b0.1%
8 b0.1% b0.1% b0.1% b0.1% b0.1% b0.1%
24–26.5 b0.1% b0.1% b0.1% b0.1% b0.1% b0.1%
γT + 1.1 mM BHT+0.5 M BTP
BHT+BTP
alone
2.9 µM
γT
6.0 µM
γT
13.9 µM
γT
27.6 µM
γT
1 b0.1% 2.7% 4.8% 5.5% 7.6%
3 2.1% 3.2% 3.9% 5.7% 7.9%
5 1.1% 2.9% 3.4% 6.3% 11.0%
8 1.3% 2.3% 3.2% 4.7% 7.4%
24–26.5 0.9% 1.8% 2.4% N4.2% N4.2%
All values are means of two to five measurements. Unless otherwise noted all data
measured by HPLC/ECD (system 3) at 22 °C were obtained from samples dissolved in
methanol:dichloromethane:acetonitrile (66.5:21.8:11.7; v/v/v) with UL10
concentrations at 1156 nM (1000 ng/ml). All values are lower after solvent degassing
(1.1- to 2.2-fold after membrane filtering or argon or nitrogen purging and 1.9- to 4.0-fold
after combined membrane filtering and argon purging). If a value is greater than a given
number, then calculation was not possible because of 100% conversion before the given
time point. Empty cells, no data generated. BHT, butylated hydroxytoluene; BTP, Bis–Tris
propane (pH6.8);αT,α-tocopherol;γT,γ-tocopherol.αT andγT levels never change over
time.
a UL10 alone at 900–3500 nM; replicated in each experiment; addition of tocol as
internal standard (≤10 µM) does not change values.
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Blood specimens from one individual (not supplemented with Q10)
that were obtained 2 days apart showed native plasma αT and UL10
levels of 45.3 and 1.1 µM in the first specimen and 75.5 and 1.1 µM in
the second specimen, applying HPLC systems 1 and 3, respectively
(Table 2). After 8 h the first and second specimens showed native
UL10 oxidation rates of 0.35 and 0.58%/h, respectively (Table 2).
Addition of EDTA to plasma (1 mM) did not change the UL10
oxidation rates.
Six separately aliquotted pooled quality control plasma samples
stored at −80 °C were spiked with known amounts of UL9:UN9
(95:5) and analyzed over the course of 3 days. System 3 showed UL10
levels of 634 nM (cv 5.3%) and UN10 levels of 27 nM (cv 7.5%) after
adjustment of UL10 for UL9 and UN10 for UN9. The adjusted mean
ratio of UL10:UN10 was 96:4 (cv 2.7%). The same analysis of another
quality control set of plasma from 13 healthy subjects revealed mean
UL10 and UN10 levels of 1466 nM (median 1479 nM, SD 660 nM) and
77 nM (median 63 nM, SD 57 nM), respectively, with a mean UL10:
UN10 ratio of 95:5 (median 96:4). A clear trend of larger UL10:UN10
ratios with lower TQ10 levels (r=−0.69; p=0.004) was observed.
The limit of quantitation for UL10 and UN10 from plasma was 23 nM.Discussion
The molar extinction coefficient of UL10 determined in this study,
3510, is in good agreement with that of UL6 (3850) reported pre-
viously [49] and validates our results. Our coulometric settings to
detect ULs and UNs, which were optimized using hydrodynamic
voltammogram results applied the oxidation–reduction–oxidation
mode with readings at the last cell [26], thereby detecting only redox-
reversible compounds leading to increased signal-to-noise ratios,
were similar to those of previous reports [5,28]. Using the same
response factors for Q9 as for Q10 in ourHPLC systemwhen convertingcoulometric responses (peak area) to molar concentrations is in
agreementwith the very similar HPLC retention times of these analogs
and with UL9 and UL10 or UN9 and UN10 exhibiting superimposable
hydrodynamic voltammograms [20].
Unexpectedly, UL10, when dissolved in organic solvents (methanol,
acetonitrile, and dichloromethane mixtures), was stable at 22 °C if
no other chemicals were present. However, when BHT or αT alone,
or particularly when BHT in combination with αT or γT, was added,
UL10 oxidized quickly to UN10 in an equimolar fashion without
formation of other products and without consumption of αT or γT.
Two aliphatic substituents (methyl or tertiary butyl residues) vicinal to
Table 2
Ex vivo UL10 oxidation rate to UN10 (%/h)
Hours UL10 UL9
Blooda: 1.0 µM UL10, 33.3 µM αT 2b b0.1%
24 b0.1%
Plasma
1.1 µM UL10, 45.3 µM αTc 3 0.07%
8 0.35%
1.1 µM UL10, 75.5 µM αTc 3 0.89%
8 0.58%
Weeks at −80 °C
0.8 µM UL10, 29.3 µM αTd 2 0.019% 0.024%
4 0.016% 0.026%
Hours
Plasma extract in hexane: 0.8 µM
UL10; 29.3 µM αTd
1 11.4% 13.4%
3 6.5% 6.4%
5 7.8% 7.3%
8 2.3% 2.1%
24–26.5 3.5% 3.4%
Unless otherwise noted all data measured after exposure to 22 °C by HPLC/ECD (system
3) were from the same subject (not supplemented with Q10); all concentrations are in
micromolar for corresponding native plasma levels. UL10, ubiquinol-10 (native);
UL9, ubiquinol-9 (spiked); αT, α-tocopherol.
a Blood was stored at the given times followed by plasma preparation and
immediate extraction into hexane and HPLC analysis (system 3).
b Same results at 6 °C.
c Collected 2 days apart.
d Using pooled plasma; no changes were observed after addition of EDTA (1 mM;
pH 6).
Fig. 4. Hypothesized mechanism of αT (aTOC-OH) catalyzing the redox cycling of UL
(HO-U-OH) to UN (O=U=O). The αT radical produced during αT's antioxidant action
toward oxidants (oxygen) is reduced by UL to αT by the formation of a UL radical. The
latter reacts quickly with oxidants (oxygen) and redox cycling of UL with oxygen is
initiated (bold reaction cycle). Phenols other than αT can act as catalysts alone or
synergistically if aliphatic (or possibly other) residues are present on both α-positions
of the phenolic hydroxyl group.
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catalytic action on UL oxidation, because aliphatic alcohols such as BTP
or nonalkylated phenols such as tocol had no effect, whereas BHT, αT,
and other phenolswith two aliphatic residues on both vicinal carbons of
the aromatic, such as 2,6-di(propan-2-yl)phenol (data not shown),
caused fast UL oxidation. The latter molecular structure is known to
enhance resonance stabilization of phenoxy radicals [50], which are
therefore likely intermediates in theobserved catalytic reaction.Phenols
with other than aliphatic residues (amines, hydroxyls, thiols) on the
vicinal carbons can most likely result in the same catalytic effect.
Because of the usual processing sequence of blood to plasma and
finally to a plasma extract we investigated the UL10 oxidation rates in
each of these three states. The UL oxidation rate was minimal in
unprocessed blood, moderate once processed to plasma, and high
once plasma was extracted into organic solvents (Table 2). The latter
finding is in good agreement with our in vitro results (Table 1), and
our overall findings are similar to those of previous reports from lipid-
phase antioxidants [51–53]. We hypothesize that during the above-
mentioned processing events the compartmentalization of lipophilic
antioxidants is increasingly destroyed through the increasing breakup
from the lipoproteins. Although relatively well preserved when
natively bound to lipoproteins, UL10 is believed to oxidize once
lipoprotein binding is broken, which allows UL10 to come into contact
with other molecules, particularly oxygen. As reported for other
micronutrients, the moderate oxidation occurring in plasma is further
diminished in unprocessed blood because of the antioxidant effects of
blood components [51–53]. Interestingly, and in agreement with our
in vitro data, we found, however, that increasing native αT levels led
to faster UL10 oxidation in native plasma (Table 2). In contrast, free
metals do not seem to contribute to the UL10 oxidation because
addition of EDTA to plasma did not change the oxidation rates.
Our findings of phenolic antioxidants catalyzing an oxidation
reaction seemed paradoxical. However, pro-oxidant properties of this
group of compounds, particularly of αT oxidizing co-antioxidants
such as quinols, are well documented [54]. Similar to the redox cycling
of lipids caused by αT [54], we hypothesize that αT can catalyze the
redox cycling of UL as shown in Fig. 4. TheαT radical produced during
αT's antioxidant action toward oxidants (oxygen) is reduced by UL
to αT under formation of a UL radical. The latter reacts quicklywith oxidants (oxygen) to form UN and redox cycling of UL to UN is
initiated (bold reaction cycle in Fig. 4). The decreased conversion
of the UL10 oxidation with increased efficiency of solvent degassing
in combination with the increased conversion caused by saturating
solvents with oxygen suggests that oxygen is the reaction partner
during the oxidation of UL10. This mechanism is supported by earlier
observations on UL10 scavenging αT radicals and reacting quickly
with oxygen [55]. The catalytic function of tocopherols during the
observed UL oxidation was confirmed by repeated analyses and the
fact that an αT change of 1–2 µM (if αT were a reaction participant)
was never observed, although well within the sensitivity of our
measurements.
We were unable to detect hydrogen peroxide by commercial
test strips (WaterWorks Peroxide Check) designed to give semiquan-
titative peroxide levels in organic solvents (data not shown). The
possibility of this test not being sensitive enough to detect H2O2 seems
unlikely, again considering that if the reaction occurred, concentra-
tions of 1–2 µM would have been generated that would have been
well within the sensitivity of the applied method (b0.5 ppm).
Therefore, the reduction of O2 was probably continued via H2O2 to
the formation of water as shown in Fig. 4.
The unavoidable oxidation tendency of UL in plasma, or particularly
once present in solution in plasma extracts with other phenolic
antioxidants, poses a critical challenge for the accurate determination
of native UL:UN ratios in the circulation. The oxidation rate is
particularly fast during the first hours and increases by difficult-to-
control factors such as temperature, storage time of plasma and
particularly its extracts, and type and concentration of phenolic plasma
antioxidants (which are unknown in part or entirely for most plasma
extracts). The former factors were realized previously [25], including
the good stability of total Q10 in plasma when stored at −80 °C over
2 yearswith orwithout several thaw–freeze cycles [20] orwhen plasma
crashed with isopropanol is stored at 0 °C up to 4 h [5].
1616 A.A. Franke et al. / Free Radical Biology & Medicine 48 (2010) 1610–1617We now report for the first time the catalytic effect of tocopherols
and other phenolic antioxidants on UL oxidation. Therefore, previous
reports have probably underestimated native plasma UL10:UN10
ratios, and assays for TQ10 probably measured the latter accurately,
assuming that sound analytical methods were applied. For TQ10
analysis we recommend the coulometric precolumn oxidation
method as established in HPLC system 2 (see Materials and methods)
because of its robustness using UV detection, high speed, and
resolution of various internal standards including tocol, retinyl
laurate, and δ-tocopheryl laurate from UN10 and also UN9 (Fig. 2B).
We propose for the first time that the application of HPLC system
3 can determine accurately native UL10 and UN10 concentrations
in the circulation by spiking known UL9 and UN9 amounts
immediately after blood draws. Because of the high similarity of
the overall molecular structures (only one isoprene unit difference
in the side chain) and the identical structural elements involved
during redox reactions, Q9 mirrors the fate of Q10 ideally, as
supported by the similar HPLC retention times, the same hydrody-
namic voltammograms, and particularly by the highly similar
oxidation rates when investigated as single agents or when present
in plasma extracts (Tables 1 and 2). Therefore, the added UL9 and
UN9 act as superb internal standards in our proposedmethod not only
by reflecting absolute analyte losses but also by reflecting the UL
oxidation rate. After adjustment of measured UL10 to UL9 and UN10
to UN9 native UL10 and UN10 levels, as occurring in the circulation,
can be calculated accurately (see Fig. 1). The key step is to add known
amounts of the internal standards to known volumes of blood or
plasma immediately after collection or preparation, respectively. This
could pose a critical challenge in epidemiologic or clinical studies
because of the constantly changing UL9:UN9 ratio in the spiking
solution, which requires UL9 and UN9 quantitation of the internal
standard solution in a calibrated analytical system on each day of
blood collection.
Very low plasma concentrations of UL9 (ca 1% vs UL10) have been
reported in humans [3] and at these levels little interference is to be
expected when UL9+UN9 are used as the internal standard. If native
Q9 needs to be measured we suggest the use of UL7/UN7, UL6/UN6,
or alkoxy ubiquinone analogs [26,29], added again in a mixture with
their ubiquinols. We showed the feasibility of the latter approach by
preparing dipropoxy and dibutoxy UN10 and UL10 analogues because
they eluted without interference and baseline separated from all
reduced and oxidized forms of Q9 and Q10 in all HPLC systems (data
not shown).
Thehigher plasmaUL10 levelswe found in the secondquality control
groupwas probably due to the large proportion of subjects supplement-
ing with Q10 in that second versus the first volunteer group. Large
differences in TQ10 concentrations between Q10 nonsupplementers
and supplementers (680–3300 nM) and, interestingly, a trendof a larger
UL10:UN10 ratio with lower TQ10 levels were observed. The latter
might be due to the body being overwhelmed with the task of keeping
Q10 reduced in the circulation when present at very large concentra-
tions or to unknown other factors.
Our findings on the catalytic effects of tocopherols and other
phenolic antioxidants on UL oxidation emphasize the high likelihood
of native UL:UN ratios to change during processing, storage, and
analysis of blood or tissue preparations. This change will be variable
and inconsistent between samples because of the variable and in
most cases unknown concentrations of catalyzing phenolic antiox-
idants in addition to unknown other cofounders such as oxygen levels
or temperature. The stability of UL10 if kept in its original
environment in blood indicates that αT does not cause considerable
UL10 oxidation physiologically or that the UL10 oxidation is counter-
acted by other antioxidant mechanisms. The proposed addition of
internal standards tracking the observed changes during blood
processing and analysis will be most helpful in future experimental,
clinical, or epidemiologic studies evaluating the role of Q10 in healthand disease by being able to accurately determine native UL10 and
UN10 levels in the matrices investigated.Acknowledgments
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